

Consumer Update

June 2022

Linagliptin acid-risk of Hypoglycemia

[EDA performs Label Update to include the following:](#)

Warnings and Precautions

Hypoglycemia with Concomitant Use with Insulin and Insulin Secretagogues

Insulin secretagogues and insulin are known to cause hypoglycemia. The risk of hypoglycemia is increased when Linagliptin is used in combination with an insulin secretagogue (e.g., sulfonylurea) or insulin

Adverse Reactions

Hypoglycemia with Concomitant Use with Insulin and Insulin Secretagogues

Drug Interactions

Insulin Secretagogues or Insulin

The risk of hypoglycemia is increased when linagliptin is used in combination with an insulin secretagogue (e.g., sulfonylurea) or insulin. Coadministration of Linagliptin with an insulin secretagogue (e.g., sulfonylurea) or insulin may require lower doses of the insulin secretagogue or insulin to reduce the risk of hypoglycemia

References: *FDA* ([Click here](#))